• IFNa targets Jak2V617F MPN stem cells.
Introduction
JAK2V617F is the most common molecular alteration in the BCR-ABL negative myeloproliferative neoplasms (MPNs). [1] [2] [3] [4] To definitively cure JAK2V617F-mediated MPN in humans, it will be necessary to eradicate all JAK2V617F mutant hematopoietic stem cells (HSCs) that solely possess the capacity to self-renew and therefore maintain the disease over time. Interferon-a (IFNa) is an effective therapy currently used in MPN patients and, importantly, it appears to be more effective than JAK2 kinase inhibitors, which inhibit the key molecular target in MPNs, at achieving molecular remissions in MPNs. [5] [6] [7] [8] Despite years of observational clinical data, the mechanism by which IFNa induces complete molecular remission (CMR) in MPN patients remains unknown. In this study, we use a conditional Jak2V617F/1E2ACre1 (hereafter Jak2 VF ) knockin murine model, in which we previously characterized the MPN-initiating stem cell population, 9 to investigate the effects of IFNa on Jak2
VF MPN stem cells in vivo. In MPN patients, the JAK2V617F mutation is detectable in the most primitive HSCs in the bone marrow 10 and in all mature cell lineages. 11, 12 JAK2V617F is also found in long-term culture initiating cells, and JAK2V617F mutant SCID repopulating cells are multi-potent and skewed toward myeloid differentiation, 13 indicating that JAK2V617F is present in functionally competent long-term HSCs (LT-HSCs). Studies in retro-viral murine models demonstrate that JAK2V617F alone is sufficient to confer an MPN disease phenotype [14] [15] [16] [17] and using a conditional Jak2V617F knockin model, we previously demonstrated that MPN-propagating cells are contained exclusively in the LT-HSC compartment. 18 All of these lines of evidence indicate that, analogous to chronic myelogenous leukemia (CML), 19 JAK2V617F-mediated MPN is maintained by a reservoir of disease-propagating stem cells that represent the ultimate therapeutic target for a definitive cure of the disease.
IFNa has a long history of efficacy in the treatment of hematological malignancies. Early studies demonstrated robust improvement in blood counts in response to IFNa treatment in patients with polycythemia vera (PV) and essential thrombocythemia. 20, 21 More recent clinical trials have demonstrated that in addition to normalizing blood counts in the majority of PV and essential thrombocythemia patients treated, IFNa reduces JAK2V617F allelic burden and, in a significant proportion (15%), renders the JAK2V617F mutant clone undetectable by sensitive molecular assays. 5, 6, 22, 23 The development of long-acting pegylated IFNa combined with the modest results shown by JAK kinase inhibitors in reducing JAK2V617F mutant allele burden in patients with myelofibrosis 8, 24 has renewed interest in the use of IFNa for the treatment of MPN. 25 Until recently, it was thought that IFNa therapy acted primarily through immunomodulatory or antiproliferative effects. 26 However, 2 studies published in 2009 employed murine models to demonstrate that IFNa can directly activate the cell cycle in quiescent, LT-HSC populations. 27, 28 These data suggest a novel mechanism by which IFNa may target primitive JAK2V617F MPN stem cell populations, leading to long-term disease eradication. In support of this hypothesis, 2 recent randomized clinical trials examined the addition of pegylated IFNa to imatinib therapy in patients with chronic-phase CML and observed a significantly higher rate of molecular response when compared with patients receiving imatinib alone, 29, 30 suggesting that IFNa targets CML-maintaining stem cells and depletes them over time.
Using a chimeric bone marrow transplant (BMT) model generated with Jak2
VF and wild-type (WT) HSCs, we assessed the effects of IFNa on Jak2 VF disease-propagating stem cells in vivo.
Materials and methods
A mouse model of Jak2 VF MPN Jak2 V617F/1 E2Acre1 (hereafter Jak2 VF ) and PCR genotyping primers were previously described.
9 Jak2 VF mice were backcrossed and maintained on C57Bl/6 background (minimum 7-8 generations). B6.Ifnar1 knockout mice were generated by Paul Hertzog. 31 Jak2 VF :WT of 2:1. Recipient mice received 11 Gy total body irradiation in equal divided doses, at least 3 hours apart within 24 hours of transplantation. All transplanted cells were injected by lateral tail vein. Mice were maintained on antibiotic (Baytril) water for 2 weeks after transplantation.
Blood analysis
Blood was collected into EDTA-coated containers and was analyzed on a Hemavet 950 analyzer (Drew Scientific).
IFNa treatment
Recombinant murine IFNa-4 was purchased (catalog no. 12110; PBL Interferon Source, Piscataway, NJ). A total of 10 000 units (correlated with the published specific activity of each batch) IFNa was diluted in phosphate buffered saline (PBS) containing 0.1% bovine serum albumin and administered by the subcutaneous route daily for 4 weeks or alternate daily for 2 weeks. 27 For the long-term (8-10 weeks) experiments, 20 000 units IFNa (Miltenyi Biotech, Teterow, Germany) was administered by subcutaneous route daily (Monday-Friday) for 8-10 weeks. Vehicle control mice received 0.1% bovine serum albumin in PBS injections.
Flow cytometry
Bone marrow, spleen, or peripheral blood were collected and prepared for staining by red blood cell lysis (BD Pharmlyse, BD Biosciences) and homogenization through a 70-mm filter. Erythroid precursor cell stainings were not pretreated with red cell lysis. All samples were analyzed by flow cytometry using FACS LSR Fortessa or LSR II (BD Biosciences). All staining steps were performed in ice-cold PBS containing 2% fetal bovine serum. Postacquisition analyses of data were performed with FlowJo software V9.2.3 (Treestar, CA). For peripheral blood chimerism studies, the following antibodies were used (clone in parentheses): CD45.1 (A20) and CD45.2 (104). For erythroid precursor cells, the following antibodies were used: CD71 (RI7217) and Ter119 (Ter-119). For stem cell and progenitor analysis, the following antibodies were used: lineage cocktail containing CD3e (145-2C11), CD5 (53-7. 3), Ter-119 (TER-119), Gr-1 (RB6-8C5), Mac-1 (M1/70), and B220 (30-F11); Kit (2B8), Sca-1 (D7), CD150 (TC15-12F12.2), CD48 (HM48-1), CD135 (A2F10), CD34 (Ram34), and CD16/32 (93) in addition to CD45.1 (A20) and CD45.2 (104). All antibodies were from Biolegend except CD45.1 Alexa 700 and CD45.2 Horizon V500 (BD Biosciences) and CD16/ 32 (eBioscience). For dead cell discrimination, Sytox blue (Invitrogen) was used. For cell cycle staining, cells were stained with the lineage cocktail. Samples were depleted of lineage-positive cells by biotin-binder Dynabeads (Invitrogen) and stained with secondary antibodies as above. Samples were then fixed and permeabilized (Fix & Perm, GAS-004; Invitrogen) as per the manufacturer's instructions and stained with anti-Ki-67 (B56; BD Bioscience) during the permeabilization stage. Finally, cells were stained with Hoechst 33342 (Invitrogen) at a final concentration of 20 mg/mL in PBS containing 2% fetal bovine serum. For apoptosis analysis, the Vybrant FAM Poly Caspases Assay Kit (catalog no. V25117; Molecular Probes, Invitrogen) was used per the manufacturer's instructions. Cells were first stained with lineage and stem cell antibodies and then with the cell permeant FAM-VAD-FMK poly caspases reagent, which detects active intra-cellular caspases, is fluorescent, and can be quantified using flow cytometry. The gating strategy used to determine LT-HSC frequency and chimerism is shown in supplemental Figure 1 . In all cases, percentage chimerism was defined as the proportion of Jak2 VF cells as a percentage of total donor cells, ie, (%CD45.2 Jak2 VF )/ (%CD45.2 Jak2 VF 1 %CD45.1 WT) 3 100%. Total engraftment ( Figure 5 ) was measured as the total percentage of CD45.2 cells in the blood of secondary transplant recipients either 4 or 16 weeks after transplantation.
Gene expression analysis

Purified Jak2
VF and WT HSC (CD150 1 LKS
1
) populations were isolated from IFNa-treated chimeric recipient mice or vehicle-treated controls (4 weeks of IFNa, n 5 4 in each group). RNA was extracted using the Picopure RNA extraction kit according to the manufacturer's instructions (Invitrogen). The samples were amplified with the Illumina Total Prepamp kit (Invitrogen) and hybridized on Illumina MouseRef-8 gene expression arrays (V2_0_R0_11278551_A). The data were analyzed with GenePattern online analysis software including quantile normalization. 32 Gene set enrichment analysis (GSEA) v2.0 was used for analysis against datasets of molecular signature datasets (www.broadinstitute.org/msigdb). 33 The microarray dataset reported in this article has been deposited in NCBI's Gene Expression Omnibus and is accessible through GEO Series accession number GSE44961 (http://www.ncbi.nlm.nih.gov/geo/query/acc. cgi?acc=GSE44961).
Statistical analysis
Data were analyzed and figures were generated with Prism for Mac OsX, V5.0 (Graphpad Software Inc.). For comparison between 2 groups, BLOOD, 2 MAY 2013 x VOLUME 121, NUMBER 18 IFNa TARGETS MPN STEM CELLS 3693
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Results
Generation of a chimeric BMT model using Jak2 VF and
WT HSCs
In this study, we used the Jak2 VF knockin model to evaluate the effects of IFNa on Jak2 VF mutant and WT hematopoietic stem and progenitor cells (HSPCs) in vivo. Because hematopoiesis in patients with MPN is comprised of a mix of both clonal MPN cells bearing somatic genetic mutations and residual polyclonal hematopoietic cells, 34 we first undertook to accurately model this heterogeneity in vivo. To do this, we generated a chimeric model of Jak2 VF Figure 1A ). After engraftment (at least 4 weeks), mice were treated with IFNa 10 000 U/d for 4 weeks or 10 000 U on alternate days for 2 weeks. To examine the effects of longer term IFNa, chimeric mice received 20 000 U/d on weekdays for 8 weeks.
Murine IFNa is effective treatment in Jak2
To determine the effects of murine IFNa on Jak2
VF MPN in vivo, we treated chimeric recipient mice with IFNa 10 000 U/d for 28 days. IFNa treatment was associated with a modest, but significant reduction in HCT, white cell count (WCC), red cell count (RCC), and hemoglobin in Jak2 VF chimeric recipients. (Figure 1B -E). There was no significant change in platelet count or total bone marrow cellularity (supplemental Figure 2A -B). IFNa treatment was well tolerated at this dose as evidenced by the absence of a significant reduction in mouse body weight (supplemental Figure 2C) . Consistent with human clinical data indicating that molecular responses require prolonged IFNa treatment to be achieved, there was no significant reduction in the percentage of Jak2 VF peripheral blood chimerism following this 28-day IFNa treatment schedule in chimeric recipient mice (supplemental Figure 2D 
IFNa reverses Jak2
VF -induced pathological extramedullary hematopoiesis
Splenomegaly and extramedullary hematopoiesis are cardinal features of JAK2V617F-induced MPN in patients and murine models of disease. 9, [35] [36] [37] [38] We found that IFNa treatment decreased extramedullary hematopoiesis as evidenced by a significant reduction in the total spleen WCC and splenic weight (Figure 2A VF transplant mice as previously described in Jak2 VF primary mice. 9 IFNa treatment resulted in a marked reduction in the total immature erythroid population of Jak2 VF chimeric mice ( Figure 2E ), whereas late erythropoiesis (CD71 low-mid Ter119 high ) was relatively preserved ( Figure 2F ). We found increased apoptosis in erythroid precursors after IFNa treatment, and again this effect was most pronounced in immature erythroid precursors ( Figure 2D ,G).
To determine if these effects were specific for the extramedullary erythropoiesis seen in Jak2 VF MPN, we treated nontransplanted primary Jak2
VF or WT mice with IFNa. We found a relative reduction in immature erythropoiesis in IFNa-treated Jak2 VF mice; however, no changes were observed in IFNa-treated WT mice (supplemental Figure 4) . In aggregate, these findings demonstrate that IFNa reverses splenomegaly due to extramedullary hematopoiesis and that IFNa induces apoptosis in Jak2
VF erythroid precursor cells, with immature erythroid precursors (CD71 
IFNa depletes Jak2
VF disease-inducing long-term stem cells
Oncogenic Jak2 VF is sufficient to engender MPN, and the expression of Jak2 VF in LT-HSC is required for the full manifestation of disease in vivo. 18 This identifies Jak2 VF LT-HSC as the exclusive reservoir of disease-initiating stem cells in vivo. IFNa has been shown to exhaust long-term WT HSC function in murine models 27, 28 and the observation that molecular responses in MPN patients can be sustained even after discontinuation of IFNa therapy 23, 25, 39 suggests Figure 3A ). Jak2 VF LT-HSCs were significantly depleted after 4 weeks of IFNa treatment ( Figure 3B ). Next, we determined the effects of IFNa treatment on myeloid-specified progenitor cell compartments using flow cytometry ( Figure 3C) . Surprisingly, IFNa treatment impaired megakaryocyte-erythroid progenitor (MEP) cell numbers in WT cells and increased granulocyte-macrophage progenitor (GMP) differentiation. In contrast, IFNa selectively increased MEP differentiation in Jak2 VF mice at the expense of GMP numbers ( Figure 3D-E) . The overall levels of apoptosis in LT-HSC populations were low and there was no significant induction of apoptosis in Jak2
VF compared with WT LT-HSC populations (supplemental Figure 5 ). These findings suggest that IFNa is not directly toxic to Jak2 VF stem cells but enforces a preexisting Jak2 VF -driven erythroid-lineage differentiation program within Jak2 VF HSCs.
9
IFNa depletes quiescent Jak2 VF disease-inducing long-term stem cells
The maintenance of a quiescent LT-HSC population is essential for long-term self-renewal and this correlates with HSC function in vivo. 40, 41 To test the hypothesis that IFNa depletes Jak2 there was a consistent reduction in G0 Jak2 VF LT-HSCs compared with WT cells. Consistent with previous reports, IFNa treatment caused activation of cell cycle in WT and Jak2 VF LT-HSCs. 27, 28 Importantly, Jak2 VF LT-HSCs were more sensitive to IFNa treatment compared with WT LT-HSCs, as evidenced by significantly reduced quiescent, but more cycling LT-HSCs in Jak2
VF compared with WT cells after IFNa treatment (Figure 4B-C) . These findings were confirmed with Hoechst 33342/ Pyronin Y staining on sorted LT-HSC-enriched populations (supplemental Figure 6) . We found similar results in primary (nontransplanted) Jak2 VF mice ( Figure 4F-G) . To determine the underlying molecular pathways that were differentially activated by IFNa treatment in Jak2 VF HSCs compared with WT HSCs, we performed gene expression profiling on purified HSC populations (lineage ). GSEA revealed significant enrichment of genes regulating cell cycle in IFNa-treated Jak2 VF HSCs compared with IFNa-treated WT HSCs ( Figure 4D ). In contrast, there was a relative enrichment of genes regulating quiescence in WT HSCs compared to Jak2 VF HSCs after IFNa treatment ( Figure 4E ). An enrichment of cell cycle genes in Jak2 VF LT-HSCs compared to WT LT-HSCs in vehicle-treated chimeric animals was also observed (supplemental Table 1 ). Finally, IFNa 27 and Stat-1 targets were nondifferentially enriched in IFNa-treated Jak2 VF and IFNa-treated WT HSCs compared with vehicle controls (data not shown). Together, these findings demonstrate that Jak2 VF LT-HSCs are preferentially sensitive to cell cycle activation by IFNa.
IFNa treatment reduces Jak2
VF MPNs in secondary transplant recipients
A defining characteristic of disease-initiating stem cells is the ability to transplant or recapitulate the disease in vivo. 9, 42 To evaluate the effects of IFNa treatment on Jak2 VF MPN-initiating cells, we performed serial transplantation experiments. A total of 5 3 10 5 bone marrow cells from vehicle-or IFNa-treated Jak2 VF chimeric mice were transplanted into lethally irradiated congenic recipient mice together with congenic helper bone marrow (1 3 10 6 cells) and recipient animals were monitored for MPN development. Recipients of bone marrow from vehicle-treated Jak2 VF chimeric mice developed elevated HCT that was present by 4 weeks after transplantation; however, recipients of bone marrow from IFNa-treated Jak2 VF chimeric mice did not ( Figure 5A ). In comparison with vehicle-treated Jak2 VF chimeric donors, IFNa-treated Jak2 VF chimeric donors demonstrated significantly reduced Jak2 VF chimerism in secondary recipients, indicating that IFNa selectively targets Jak2 VF MPN-initiating cells ( Figure 5B ). Finally, there was significantly reduced total engraftment in recipient mice that received IFNa-treated bone marrow, with a selective For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From reduction in the engraftment of IFNa-treated Jak2 VF bone marrow over IFNa-treated WT bone marrow ( Figure 5C ). This demonstrates preferential depletion of functional repopulating Jak2 VF LT-HSCs compared with WT LT-HSCs after IFNa. The effects on Jak2 VF chimerism and total engraftment were sustained up to 16 weeks after transplantation ( Figure 5D-E) , although persistent, long-term, low-level Jak2
VF engraftment was present in all recipient mice. The reduction in secondary transplantation of disease was confirmed at an increased cell dose (2 3 10 6 donor bone marrow cells). For vehicle-treated chimeric donors, 4 of 4 recipients of the 2 3 10 6 cell dose demonstrated elevated HCT 4 and 16 weeks after transplantation. In contrast, for IFNa-treated chimeric donors, 1 of 4 recipients of the 2 3 10 6 cell dose demonstrated elevated HCT 4 weeks after transplantation and 3 of 4 recipients had elevated HCT 16 weeks after transplantation. These findings demonstrate that IFNa treatment depletes functional Jak2 VF diseaseinitiating stem cells and impairs the transmission of Jak2 VF MPN in vivo and suggest that in the absence of sustained treatment with IFNa, Jak2 VF MPN-propagating stem cells can persist and maintain disease.
The effects of IFNa are cell autonomous and mediated through type 1 interferon signaling
To determine whether the effects on Jak2 VF LT-HSCs were cell autonomous and specific to type 1 interferon signaling, we established chimeric recipient mice from Jak2 VF or Jak2 VF IFNa receptor null (Ifnar1 2/2 ) donors. 31 These chimeric recipients were ;70% Jak2 VF CD45.2 and 30% WT CD45.1. Chimeric recipient mice were treated with 10 000 U/d IFNa for 4 weeks. Consistent with the previous data, IFNa treatment caused a significant reduction in the WCC and RCC in the peripheral blood of chimeric mice, whereas no changes were seen in Jak2 VF Ifnar1 2/2 chimeras ( Figure 6A-B) . Furthermore, extramedullary hematopoiesis, as evidenced by spleen size and spleen WCC, was reduced in Jak2 VF chimeras after IFNa treatment and these changes were not seen in Jak2 chimeras ( Figure 6E-F) . There was a reduction in total LT-HSC numbers in Jak2 VF chimeras after treatment with IFNa; however, there was no change in total LT-HSC numbers in Jak2 Figure 6G ). Finally, treatment with IFNa led to a reduction in the G0 (quiescent) HSC population and an increase in the actively cycling HSC population in Jak2 VF cells. However, there was no change to cell cycle in Jak2
VF
Ifnar1
2/2 chimeras after treatment with IFNa ( Figure 6H-J) . Together, these data demonstrate that the effects of IFNa on Jak2 VF HSCs are specific to type 1 interferon signaling and are cell autonomous. Moreover, these data confirm the effects of IFNa treatment in a system that is biased toward a higher Jak2 VF chimeric burden.
Discussion
IFNa treatment achieves molecular remissions in MPN patients, 5, 6, 22 and in murine models, IFNa has been shown to exhaust long-term WT HSC function. 27, 28 In aggregate, these results suggest that IFNa may eliminate the JAK2V617F mutant clone in MPN patients by preferentially targeting JAK2V617F MPN-propagating stem cells and depleting them over time. However, because the JAK2V617F allelic burden is typically quantified in peripheral blood granulocytes and because the majority of clonal expansion in MPN occurs in progenitor cells, it is plausible that patients that have no detectable JAK2V617F in granulocytes could still have a reservoir of JAK2V617F mutant HSC that persists. Indeed, JAK2V617F mutant colonies can be detected at a low level in some MPN patients in CMR. 43 Intriguingly, several groups have reported long-term molecular responses after discontinuation of IFNa therapy, suggesting that JAK2V617F mutant HSCs are being eradicated by IFNa, 23 ,25,39 although molecular relapse after cessation of IFNa has also been observed. 44 In this study, we use a conditional knockin murine model of Jak2V617F-induced MPN to investigate the effects of IFNa on Jak2 VF mutant and WT LT-HSC in vivo and to evaluate the means by which IFNa eradicates Jak2 VF mutant cells in MPN. Given the clinical IFNa data as outlined and the experimental evidence demonstrating the effects of IFNa on HSC homeostasis, 27, 28, 45, 46 we focused on the HSC compartment. We have not observed differences in LT-HSC numbers at steady state in primary Jak2 VF compared with WT mice. 9 We find that Jak2 VF MPN stem cells are preferentially sensitive to IFNa therapy with depletion of Jak2 VF LT-HSC over time. We show that IFNa treatment promotes the exit from quiescence of Jak2 VF LT-HSC and Jak2
VF -induced terminal erythroid differentiation. Using flow cytometry and gene expression profiling performed on populations enriched for LT-HSC activity (CD1501LKS1), we show that Jak2
VF LT-HSC demonstrate enhanced cell cycle (E) MEP differentiation was potentiated by IFNa treatment in Jak2 VF chimeric mice compared with vehicle controls (76.4 6 1.7% vs 56.9 6 4.4%, respectively; P , .01), but there was no effect in Ifnar1 2/2 Jak2 VF chimeric mice compared with vehicle controls (53.4 6 2.7% vs 51.3 6 4.4%, respectively; P 5 .69). (F) GMP differentiation was impaired in IFNa-treated Jak2 VF chimeric mice compared with vehicle controls (17.1 6 1.5% vs 31.7 6 3.3%, respectively; P , .01), but there was no effect in IFNa-treated For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From activation compared with WT LT-HSC, in response to treatment with IFNa. Using Ifnar1 knockout mice, we demonstrate that the effects of IFNa on cell cycle are cell autonomous and specifically mediated through type 1 interferon signaling. In vehicle-treated mice, we find a more activated cell cycle in Jak2 VF LT-HSCs compared with WT LT-HSCs, and consistent with this, GSEA indicated an enrichment of cell cycle genes in Jak2 VF LT-HSCs compared with WT LT-HSCs in vehicle-treated chimeric animals. We previously reported no difference in cell cycle between Jak2 VF and WT cells, but this earlier analysis was performed on less purified total LKS1 cells from nontransplanted primary mice. 9 In aggregate, these results indicate that Jak2
VF LT-HSCs demonstrate enhanced cell cycle activity at baseline and preferential sensitivity to cell cycle activation in response to IFNa treatment.
The apparently paradoxical finding of enhanced LT-HSC cell cycling and enhanced self-renewal has been demonstrated in other MPN models. We previously reported a subtle self-renewal advantage for Jak2 VF LT-HSC, 18 and in the present study, we find enhanced cell cycle activity in Jak2 VF LT-HSC compared with WT LT-HSC in vehicle-treated chimeric mice. Interestingly, Reynaud et al 47 recently reported, using a murine transgenic BCR-ABL model, that CML LT-HSC also demonstrate enhanced cycling that occurs together with a gain in LT-HSC self-renewal and similar findings have been reported in a transgenic JAK2V617F MPN model. 48 The exact mechanisms underlying these findings remain unclear; however, altered regulation of key self-renewal pathways (eg, Notch) may play a role. 47, 49 Our data evaluating the effects of IFNa indicate that Jak2 VF LT-HSCs are preferentially sensitive to IFNa treatment by showing a more marked increase in cycling, which results in a preferential depletion in response to IFNa. This sensitivity may occur as a result of baseline cell cycle activation in Jak2 VF MPN stem cells. These data also suggest that increased cell cycle may not be the sole mechanism by which IFNa depletes Jak2 VF LT-HSCs, because vehicle-treated Jak2 VF LT-HSCs also have increased cell cycling but do not undergo depletion during long-term BMT assays. Additional studies aimed at identifying key cell cycle and self-renewal modulators differentially regulated at baseline and in response to IFNa treatment in Jak2 VF and WT LTHSCs remain an ongoing focus of our work. Finally, we also note that the Jak2 VF LT-HSC competitive repopulation advantage we previously found became manifest with prolonged follow-up (.1 year) 18 and our findings in the present study, where Jak2 VF LT-HSCs have no significant repopulating advantage at 8 weeks ( Figure 3B ), are consistent with this. In the present study, we find no significant difference in the engraftment of Jak2 VF vehicle-treated cells compared with WT vehicle-treated cells at 16 weeks in a secondary BMT assay ( Figure 5E ). It is not clear why a self-renewal advantage is not seen in this secondary BMT; however, it is possible that a change in competitive repopulation ability is too subtle to be observed after only 16 weeks posttransplantation. Alternatively, we cannot exclude that the late clonal advantage observed could occur as a result of the acquisition of secondary mutations.
Notably, depletion of Jak2 VF LT-HSC was observed only in IFNa-treated mice, and importantly, depletion of the MPNpropagating stem cell population was associated with reduced MPN transplantation efficiency in serially transplanted recipient mice. Serial transplantation is the most stringent functional assay to assess effects on the disease-initiating stem cell population, and these experiments indicate that sustained IFNa treatment targets MPN-propagating HSC in vivo. The presence of persistent lowlevel Jak2
VF chimerism after IFNa treatment in serially transplanted mice suggests that IFNa may not be sufficient to completely eradicate Jak2 VF LT-HSCs or that a significantly prolonged IFNa treatment course may be required for definitive disease eradication. We do not find any evidence to indicate that IFNa treatment in vivo has proapoptotic effects on LT-HSCs and the absence of a reduction in Ifnar1 2/2 Jak2 VF HSCs in response to 4 weeks of continuous IFNa treatment argues strongly against an immune-mediated depletion of Jak2 VF cells. These results are also consistent with human clinical trials in MPN, in which at least 1 year of IFNa therapy was required for CMR to be achieved. 5, 6 In aggregate, our results indicate that IFNa has differential effects on Jak2 VF and normal WT LT-HSCs in vivo and suggest that the durable molecular remissions induced by IFNa in patients with MPN occur as a result of MPN stem cell exhaustion through activated cell cycling and enforced differentiation.
The Jak2 VF model we use in this study closely recapitulates the features of human PV and we have exploited this to evaluate the effects of IFNa on Jak2 VF erythropoiesis in vivo. We find that IFNa treatment selectively expands the Jak2 VF MEP compartment in the bone marrow by driving Jak2 VF LT- -mediated splenomegaly that we find in response to IFNa treatment and are consistent with the known sensitivity of JAK2V617F erythroid colonies to IFNa treatment in vitro. 50 We find that the reduction in HCT is modest after 4 weeks of IFNa treatment but that the HCT is normalized after 8 weeks of IFNa treatment, a finding likely related to the prolonged life span of a mature RBC. In aggregate, these results indicate that IFNa exerts distinct effects on different Jak2 VF hematopoietic cellular compartments, activating Jak2
VF LT-HSCs to induce differentiation while inducing apoptosis in Jak2 VF erythroid precursor cells to normalize RBC counts. Although IFNa clearly has therapeutic efficacy in MPN, it is far from an ideal treatment and remains an experimental MPN therapy at present. 25 One of the major challenges in the clinical use of IFNa is poor patient tolerability due to the multitude of side effects IFNa causes. Although these have improved with the use of lower dosing and pegylated forms of the drug, many patients remain intolerant of IFNa. Future studies aimed at identifying unique IFNa effector pathways in Jak2 VF MPN stem cells have the potential to facilitate the development of more specific, less toxic IFNa derivatives for the treatment of MPN. This work also provides support for the rational combination of IFNa with new agents with promising but incomplete activity in MPN, including the JAK2 inhibitors. Combinatorial IFNa/ JAK2 inhibitor treatment may be therapeutically synergistic as a result of IFNa-mediated induction of cell cycle in quiescent Jak2 VF LT-HSCs coupled with the antiproliferative effects of JAK2 kinase inhibition in progenitor cells. Finally, it is important to note that only a minority of MPN patients achieves a CMR in response to IFNa treatment. Part of the heterogeneity in response may be related to the presence of other genetic abnormalities, in addition to JAK2V617F, in some patients. Emerging evidence suggests that TET2 and DNMT3A mutations may contribute to IFNa resistance in MPN. 43, 51, 52 Given the key roles of TET2 53, 54 and DNMT3A 55 in HSC homeostasis, it will be important to investigate the mechanisms of this resistance as a means to further delineate the specific effects of IFNa on MPN-propagating stem cells.
In conclusion, we report the therapeutic efficacy of IFNa on Jak2
VF disease-initiating LT-HSCs in vivo, a finding consistent with that previously reported in abstract form by Marty et al. 56 We demonstrate that IFNa preferentially depletes Jak2 VF MPNpropagating stem cells by activating cell cycle and promoting Jak2 VF -driven erythroid-lineage differentiation. Through this work, we offer insights into the mechanism by which IFNa achieves CMR in MPN patients and provide a biological rationale in support of combinatorial IFNa/JAK2 inhibitor clinical trials in MPN patients.
